News from Bayer
November 11, 2022
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity
November 08, 2022
Third quarter of 2022
Bayer with continued strong performance
October 17, 2022
Not intended for U.S. and UK Media
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy